Skip to main
CAI

CAI (CAI) Stock Forecast & Price Target

CAI (CAI) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Caris Life Sciences is a promising AI TechBio company with strong revenue and clinical volume projections, poised to become profitable in 2026. With plans for expansion, success in new test launches, and entry into the early cancer detection market, they have a comprehensive platform and strong market share for the growing field of precision oncology. While there are risks and competition, the company's recent IPO success and strong management team are positive indicators for their future growth potential.

Bears say

Caris Life Sciences is facing multiple headwinds that are giving financial analysts a negative outlook on their stock. The company is facing competition in the precision oncology market, and may need to raise additional capital to stay competitive. Furthermore, delays in the launch of their newest test and uncertainty in the capital markets have also raised concerns. In addition, the company may struggle with slower revenue growth from their liquid biopsy test and increasing competition in the precision oncology testing space. Despite having a strong pipeline and growing clinical case volumes, these challenges may impact the company's financial performance in the future.

CAI (CAI) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CAI and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CAI (CAI) Forecast

Analysts have given CAI (CAI) a Buy based on their latest research and market trends.

According to 8 analysts, CAI (CAI) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CAI (CAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.